Amniotic mesenchymal stem cells with robust chemotactic properties are effective in the treatment of a myocardial infarction model

24Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Background: We previously reported that amniotic mesenchymal stem cells (AMMs) possess high angiovasulogenic properties. In this study, we investigated the chemotactic abilities of AMMs for improved cardiac function and regenerative angiogenesis. Methods: The expressions of chemotactic and angiogenic geneswere determined by qRT-PCR.Myocardial infarction (MI) was induced in NOD/SCID mice and cells were directly transplanted into the border regions of ischemic heart tissue. Immunohistochemical analysis was also conducted. Results: AMMs significantly expressed the representative chemotactic factor GCP-2, NAP-2 as well as angiogenic factor Hif-1a. AMMs also highly expressed the chemokine receptors CCR2, CCR3 and CCR5. AMMtransplantation improved left ventricular function, capillary density, angiogenic cytokine levels, angiopoetin (Ang)-1 and vascular endothelial growth factor (VEGF-A) levels in affected tissue. Immunohistochemical assaying also revealed increased engraftment and endothelial phenotypes. Conclusion: Our findings suggest that due to elevated survival and related chemotactic potential, AMMs are a promising stem cell source for the treatment of ischemic cardiovascular disease. © 2012 Elsevier Ireland Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Kim, S. W., Zhang, H. Z., Kim, C. E., Kim, J. M., & Kim, M. H. (2013). Amniotic mesenchymal stem cells with robust chemotactic properties are effective in the treatment of a myocardial infarction model. International Journal of Cardiology, 168(2), 1062–1069. https://doi.org/10.1016/j.ijcard.2012.11.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free